Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. | AVESİS

Istanbul University Research Information System

Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.

Gruenwald V., Karakiewicz P. I. , Bavbek S. E. , Miller K., Machiels J. H. , Lee S., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)

Publication Type: Article / Abstract
Volume: 29 Issue: 15
Publication Date: 2011
Title of Journal : JOURNAL OF CLINICAL ONCOLOGY